{
    "clinical_study": {
        "@rank": "26832", 
        "acronym": "PANC-001", 
        "arm_group": {
            "arm_group_label": "Abraxane with Gemcitabine", 
            "arm_group_type": "Experimental", 
            "description": "Abraxane at 125 mg/m2, IV infusion over 30 to 40 minutes (maximum infusion time not to exceed 40 minutes) followed by gemcitabine at 1000 mg/ m2 IV infusion over 30 to 40 minutes given once weekly for 3 weeks (Days 1, 8 and 15) followed by a week of rest (28 day cycle)."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the safety and efficacy of Abraxane combined with\n      Gemcitabine in Chinese patients with metastatic pancreatic cancer."
        }, 
        "brief_title": "Safety and Efficacy Study of Abraxane Plus Gemcitabine in Chinese Patients With Metastatic Pancreatic Cancer", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Pancreatic Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Pancreatic Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a Phase 2 trial in China to evaluate the safety and efficacy of the combination of\n      Abraxane and gemcitabine administered in patients diagnosed with metastatic pancreatic\n      adenocarcinoma.  Approximately 82-246 patients are planned to be accrued.  This study is\n      designed to be a Chinese bridging study to complement the Global pivotal study (CA-046).\n\n      The study consists of three parts: (1) Dose evaluation; (2) Single arm to evaluate efficacy\n      following an optimal Simon two-stage design; and (3) Randomized 2-arm to evaluate the\n      efficacy and safety of Abraxane plus gemcitabine versus gemcitabine alone. These 3 parts\n      will be carried out sequentially.  The Part 3 randomized 2-arm portion will only be carried\n      out if deemed necessary per protocol."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patient has definitive histologically or cytologically confirmed metastatic\n             pancreatic adenocarcinoma (Islet cell neoplasms are excluded) that is measurable by\n             RECIST\n\n          2. Patients must have received no previous radiotherapy, surgery, chemotherapy or\n             investigational therapy for the treatment of metastatic pancreatic cancer.  Prior\n             treatment with 5-FU or gemcitabine administered as a radiation sensitizer in the\n             adjuvant setting is allowed, provided at least 6 months have elapsed since completion\n             of the last dose and no lingering toxicities are present.  Patients having received\n             cytotoxic doses of gemcitabine or any other chemotherapy in the adjuvant setting are\n             not eligible for this study\n\n          3. Patient has a Karnofsky performance status (KPS) \u2265 70\n\n          4. Initial diagnosis of metastatic disease must have occurred \u2264 6 weeks prior to\n             starting Cycle 1 Day 1.  NOTE: the clock for this time interval starts with the date\n             of last evaluation confirming pancreatic metastatic disease (either biopsy or imaging\n             results)\n\n          5. Patients should be asymptomatic for jaundice prior to Cycle 1 Day 1.  Significant or\n             symptomatic amounts of ascites should be drained prior to Cycle 1 Day 1.  Pain\n             symptoms should be stable and should not require modifications in analgesic\n             management prior to Cycle 1 Day 1\n\n          6. Patient has adequate blood counts at Screening (obtained \u2264 14 days prior to starting\n             Cycle 1 Day 1):\n\n               -  Absolute neutrophil count (ANC) \u2265 1.5 \u00d7 10^9/L;\n\n               -  Platelet count \u2265 100,000/mm3 (100 \u00d7 10^9/L);\n\n               -  Hemoglobin (Hgb) \u2265 9 g/dL\n\n          7. Patient has the following blood chemistry levels at Screening (obtained \u2264 14 days\n             prior to starting Cycle 1 Day 1):\n\n               -  Aspartate Aminotransferase (SGOT) and Alanine Transaminase (SGPT) are \u2264 2.5 \u00d7\n                  upper limit of normal range , unless liver metastases are clearly present, then\n                  \u2264 5 \u00d7 upper limit of normal range is allowed\n\n               -  Total bilirubin \u2264 upper limit of normal range\n\n               -  Serum creatinine within normal limits or calculated clearance \u2265 60 mL/min/1.73\n                  m2 for patients with serum creatinine levels above or below the institutional\n                  normal value.  If using creatinine clearance, actual body weight should be used\n                  for calculating creatinine clearance (eg, using the Cockroft-Gault formula).\n                  For patients with a Body Mass Index (BMI) > 30 kg/m2, lean body weight should be\n                  used instead.\n\n          8. Patient has acceptable coagulation studies (obtained \u226414 days prior to starting Cycle\n             1 Day 1) as demonstrated by prothrombin time (PT) and partial thromboplastin time\n             (PTT) within normal limits (\u00b115%).  (See also Section 6.2 for Screening PT/PTT\n             analysis).\n\n          9. Patient has no clinically significant abnormalities in urinalysis results (obtained\n             \u226414 days prior to starting Cycle 1 Day 1).\n\n         10. Male or non-pregnant and non-lactating female, and \u2265 18 years of age at the time of\n             signing the informed consent document.\n\n               -  If a female patient is of child-bearing potential, as evidenced by regular\n                  menstrual periods, she must have a negative pregnancy test (e.g. serum \u03b2-hCG)\n                  documented prior to the first administration of study drug.\n\n               -  If sexually active, the patient must agree to use contraception considered\n                  adequate and appropriate by the Investigator during the period of administration\n                  of study drug.  In addition, male and female patients must utilize contraception\n                  after the end of treatment as recommended in the product's Prescribing\n                  Information provided in the study manual.\n\n         11. Patient has been informed about the nature of the study, and has agreed to\n             participate in the study, and signed the Informed Consent Form prior to participation\n             in any study-related activities.\n\n         12. Able to adhere to the study visit schedule and other protocol requirements.\n\n        Exclusion Criteria:\n\n        Patient has known brain metastases 2. Patient has only locally advanced disease. 3.\n        Patient has a \u2265 20% decrease in serum albumin level between Screening visit and within 72\n        hours prior to Cycle 1 Day 1.\n\n        4. History of malignancy in the last 5 years (including chronic leukemias).  Patients with\n        prior history of in situ cancer or basal or squamous cell skin cancer are eligible.\n        Patients with other malignancies are eligible if they were cured by surgery alone or\n        surgery plus radiotherapy and have been continuously disease-free for at least 5 years.\n\n        5. Patient has active, uncontrolled bacterial, viral, or fungal infection(s) requiring\n        systemic therapy.\n\n        6. Patient has known infection with Human Immunodefiency Virus, and/or  active infection\n        with hepatitis B, or hepatitis C (patients with known historical infection with hepatitis\n        B or C should be discussed with the Sponsor).\n\n        7. Patient has undergone major surgery, other than diagnostic surgery (ie, surgery done to\n        obtain a biopsy for diagnosis without removal of an organ), within 4 weeks prior to Day 1\n        of treatment in this study.\n\n        8. Patient that has a history of a myocardial infarction, severe/unstable angina pectoris,\n        coronary/peripheral artery bypass graft, New York Heart Association (NYHA) Class III-IV\n        heart failure, uncontrolled hypertension, clinically significant cardiac dysrhythmia or\n        electrocardiogram (ECG) abnormality, cerebrovascular accident,  transient ischemic attack,\n        seizure disorder or clinically significant cardiac dysrhythmia or electrocardiogram (ECG)\n        abnormality, within 6 months prior to Cycle 1 Day 1 9. Patient has a history of allergy or\n        hypersensitivity to any of the study drugs or any of their excipients, or the patient\n        exhibits any of the events outlined in the Contraindications or Special Warnings and\n        Precautions sections of the product or comparator Prescribing Information.\n\n        10. History of connective tissue disorders (eg, lupus, scleroderma, arteritis nodosa).\n\n        11. Patients with a history of interstitial lung disease , history of slowly progressive\n        dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis,\n        pulmonary hypersensitivity pneumonitis or multiple allergies.\n\n        12. Patient has any condition, including serious medical risk factors, medical conditions,\n        laboratory abnormalities or psychiatric disorders, which could compromise the patient's\n        safety or the study data integrity.\n\n        13. Patient is enrolled in any other clinical protocol or investigational trial with an\n        interventional agent or assessments that may interfere with study procedures.\n\n        14. Patient is unwilling or unable to comply with study procedures, or is planning to take\n        vacation for 7 or more consecutive days during the treatment phase of the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "82", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02017015", 
            "org_study_id": "ABI-007-PANC-001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Abraxane with Gemcitabine", 
                "description": "Abraxane in combination with gemcitabine used in the initial treatment of metastatic pancreatic cancer for that patient", 
                "intervention_name": "Abraxane", 
                "intervention_type": "Drug", 
                "other_name": "ABI-007 and Gemzar"
            }, 
            {
                "arm_group_label": "Abraxane with Gemcitabine", 
                "description": "Abraxane in combination with gemcitabine used in the initial treatment of metastatic pancreatic cancer for that patient", 
                "intervention_name": "Gemcitabine", 
                "intervention_type": "Drug", 
                "other_name": "Abraxane in combination with gemcitabine used in the initial treatment of metastatic pancreatic cancer for that patient"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Pancreatic cancer", 
            "Metastatic pancreatic cancer", 
            "treatment for pancreatic cancer", 
            "Abraxane clinical research trials", 
            "Celgene clinical research trials"
        ], 
        "lastchanged_date": "March 10, 2014", 
        "location": [
            {
                "contact": {
                    "phone": "(+86) 88196175"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China"
                    }, 
                    "name": "Beijing Cancer Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "(+86) 69158315"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China"
                    }, 
                    "name": "Peking Union Medical College Hospital"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "phone": "(+86) 87343228"
                }, 
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China"
                    }, 
                    "name": "Sun Yat Sen University Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "(+86) 86006922"
                }, 
                "facility": {
                    "address": {
                        "city": "Hangzhou", 
                        "country": "China"
                    }, 
                    "name": "Sir Run Run Shaw Hospital Zhejiang University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "(+86) 56731277"
                }, 
                "facility": {
                    "address": {
                        "city": "Hangzhou", 
                        "country": "China"
                    }, 
                    "name": "The First Affiliated Hospital of Medical School of Zhejiang"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "phone": "(+86) 83284620"
                }, 
                "facility": {
                    "address": {
                        "city": "Nanjing", 
                        "country": "China"
                    }, 
                    "name": "Jiangsu Provincial Tumor Hospital"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "phone": "(+86) 63240090"
                }, 
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China"
                    }, 
                    "name": "Shanghai First People's Hospital"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2, Multi-center Study to Evaluate the Safety and Efficacy of ABI-007 Plus Gemcitabine in Chinese Patients With Metastatic Pancreatic Adenocarcinoma", 
        "overall_contact": {
            "email": "clinicaltrialdisclosure@celgene.com", 
            "last_name": "Associate Director Clinical Trial Disclosure", 
            "phone": "1-888-260-1599"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The percentage of patients considered to have responded to therapy based on objective response rate by independent radiological review.", 
            "measure": "Objective Response Rate", 
            "safety_issue": "No", 
            "time_frame": "18 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02017015"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "This analysis will only be conducted for patients that have a complete response or partial response. Defined as the time from first tumor assessment when the complete response/partial response criteria is met to the date of disease progression.", 
                "measure": "Duration of response according to RECIST 1.0 guidelines", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "description": "Number of patients alive", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "description": "Number of patients with adverse events", 
                "measure": "Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "19 months"
            }
        ], 
        "source": "Celgene Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Celgene Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}